Diverse patent strategies essential, foreign lawyer says

Korean drug companies who intend to make inroad to the U.S. market need to make a careful review on patents listed in the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) as part of plan to avoid any possible patent suits there, a foreign lawyer said Tuesday.

In an international seminar held at Seoul National University, a U.S. lawyer Dzwonczyk said that if Korea...